High tumor-infiltrating FoxP3+ T cells predict poor survival in estrogen receptor-positive breast cancer: a meta-analysis

Publication date: Available online 30 January 2017
Source:European Journal of Surgical Oncology (EJSO)
Author(s): Qian Feng, Qingping Yang, Linquan Wu, xiaojin Huang, Rongshou Wu, Shanshan Rao, Wenjun Liao, Yong Huang, Enliang Li
AimsTumor-infiltrating FoxP3⁺ T cells and FoxP3⁺ tumor cells have been reported in breast cancer (BC), which impaired immunity and promoted tumors progression. However, their prognostic value for survival in patients with breast BC remains controversial.MethodsA meta-analysis was performed. Original data included the hazard ratios (HR) of overall survival (OS), relapse-free survival and odds ratio (OR) in BC patients. We pooled HR/OR with 95% confidence intervals (CI) to estimate the hazard.ResultsThe overall survival of high tumor-infiltrating FoxP3⁺ T cells patients was lower than low tumor-infiltrating FoxP3⁺ T cells patients with estrogen receptor (ER)-positive (HR 0.86, 95% CI 0.77-0.96; P=0.009) but not ER-negative (HR 1.09, 95% CI 0.82-1.45; P=0.569) BC. And FoxP3⁺ tumor cells were not associated with the overall survival and recurrences of BC patients (P>0.05). In addition, a significant association was revealed between high tumor-infiltrating FoxP3⁺ T cells and grade (Ⅰ+Ⅱ/Ⅲ: OR 0.31, 95% CI 0.17-0.56; P<0.001), ER status (present: OR 2.39, 95% CI 1.51-3.76; P<0.001), HER2 status (present: OR 0.53, 95% CI 0.36-0.78; P=0.001), PR status (present: OR 1.88, 95% CI 1.31-2.71; P<0.001). And a significant association was revealed between positive FoxP3⁺ tumor cells and Nodal status (present: OR 0.48, 95% CI 0.23-0.97; P=0.04), grade (Ⅰ+Ⅱ/Ⅲ: OR 0.44, 95% CI 0.22-0.85; P=0.01), PR status (present: OR 2.37, 95% CI 1.54-3.36; P<0.001).ConclusionsHigh tumor-infiltrating FoxP3⁺ T cells were associated with a poorer prognosis for ER-positive BC, but not for ER-negative BC.



http://ift.tt/2k9sMhr